Researchers reported that once-weekly semaglutide can reduce heavy drinking days in people with alcohol use disorder and obesity, based on results published in The Lancet from a small trial. The study focuses on GLP-1 receptor agonist effects on alcohol consumption behavior and adds a new behavioral target for an established metabolic drug class.